AstraZeneca PLC is set to make regulatory filings worldwide in the coming months to expand the label for its SGLT2 inhibitor Farxiga (dapagliflozin) to include patients with chronic kidney disease, both with and without type 2 diabetes, on the basis of the data from the DAPA-CKD study.
DAPA-CKD was stopped early in March because of “overwhelming efficacy” and in July, AstraZeneca revealed that it had shown a significant and clinically meaningful effect on its primary endpoint of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?